Program Director:
Ranjan Duara, MD
Medical Director, Wien Center for Alzheimer's Disease and Memory Disorders
Mount Sinai Medical Center
Miami Beach, FL

Full list of our speakers

Mild Cognitive Impairment (MCI) Symposium 2013

Predicting and Measuring Progression in Early Alzheimer's Disease (AD)

Saturday, JANUARY 19, 2013
7:00 am – 7:30 pm

7:00 – 8:00 am	Breakfast Buffet
8:00 – 8:15 am	Welcome and Introduction	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
8:15 – 10:45 am	Mini – Symposium 1 Predictors of Progression to MCI and AD (Epidemiology) Chair: Mary Ganguli, MD, MPH, University of Pittsburgh, Pittsburgh, PA
	1. New Approaches to Understanding the Relationships of Risk Factors to Cognitive Decline	David A. Bennett, MD Rush Medical School, Chicago, IL
	2. The Flynn Effect; How Secular Changes Influence the Predictive Value of Cognitive Performance and the Role of Computer Tomography in Prodromal Dementia in the H70 Study in Gothenburg, Sweden	Simona Sacuiu, MD, PhD Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
	3. Rates and Predictors of Progression from Mild Cognitive Impairment to Dementia: The Mayo Clinic Study of Aging	Rosebud Roberts, MB, ChB Mayo Clinic, Rochester, MN
	4. Risk Factors for Age of Onset of AD in the Cache County Study	Peter Rabins, MD, MPH Johns Hopkins University, Baltimore, MD
	5. The Fluidity of MCI in the Community and the Role of Vascular Biomarkers in Predicting Progression in the Indianapolis-Ibadan Study	Hugh Hendrie, MB, ChB, DSc Indiana University, Indianapolis, IN
	6. Risk Factors for MCI Development and for MCI Progression: Are They The Same?	Mary Ganguli, MD, MPH University of Pittsburgh, Pittsburgh, PA
10:45 – 11 am	Break
11:00 am – Noon	Open Discussion Discussant: Ronald Petersen, MD, PhD, Mayo Clinic, Rochester, MN
Noon – 1 pm	LUNCH
1:00 – 2:00 pm	Keynote Lecture: Solving the Dilemma of Treatment Versus Prevention Strategies for Alzheimer's Disease Todd Golde, MD, PhD, University of Florida, Gainesville, FL
2:00 – 4:15pm	Mini – Symposium 2 Utility of Biomarkers for Predicting and Measuring Progression in Normal Aging, MCI and AD Chair: Tammie Benzinger, MD, PhD, Washington University School of Medicine, St. Louis, MO
	1. The Cortical Signatures of Alzheimer's Disease and Frontotemporal Degeneration: Quantitative MRI Biomarkers Detectable prior to Dementia	Brad Dickerson, MD, MMSc Harvard Medical School, Boston, MA
	2. Biomarkers, Cognitive Reserve and Cognition in Alzheimer's Disease	Prashanthi Vemuri, PhD Mayo Clinic, Rochester, MN
	3. Neuroimaging for Predicting and Measuring Progression in Preclinical Autosomal Dominant Alzheimer's Disease	Tammie Benzinger, MD, PhD Washington University School of Medicine, St. Louis, MO
	4. MRI, FDG-PET and EEG for Predicting Progression in Aging, MCI and AD	Philip Scheltens, MD, PhD VU Medical Center, Amsterdam, Netherlands
	5. Highlights of Biomarker and Clinical Outcomes from Recent AD Treatment Trials	Stephen Salloway, MD, MS Brown Medical School, Providence, RI
4:15 – 4:30	Break
4:30 – 5:30 pm	Open Discussion Discussant: Victor Villemagne, MD, Austin Health, University of Melbourne, Melbourne, Australia
5:30 – 7:30 pm	NETWORKING RECEPTION

Early Alzheimer's Disease Workshop

Alzheimer's Disease Prevention Trials

Sunday, JANUARY 20, 2013
8:00 am – 1:30 pm

7:00 – 8:00 am	Breakfast Buffet
8:00 am – 8:10	Introduction to the Workshop	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
8:10 – 9:00 am	Keynote Lecture: Launching the Era of Alzheimer's Prevention Research	Eric M. Reiman, MD Banner Alzheimer's Institute, Phoenix, AZ
9:00 – 11:15am	Challenges in Treating Preclinical Alzheimer's Disease Chair: Reisa A. Sperling, MD, MMSc, Massachusetts General Hospital and Harvard Medical School, Boston, MA
	1. A New Era: DIAN and the Secondary Prevention of Symptomatic Alzheimer's Disease	John C. Morris, MD Washington University School of Medicine, St. Louis, MO
	2. Anti-Amyloid Treatment of Asymptomatic Alzheimer's Disease: The A4 Study	Reisa A. Sperling, MD, MMSc, Massachusetts General Hospital and Harvard Medical School, Boston, MA
	3. The Role of Fluid Biomarkers in Preclinical Alzheimer's Treatment Trials	Anne M. Fagan, PhD Washington University School of Medicine, St. Louis, MO
	4. The Role of Amyloid Imaging in Preclinical Alzheimer's Treatment Trials	Adam S. Fleisher, MD, MAS Banner Alzheimer's Institute, Phoenix, AZ
	5. Addressing the Ethical Challenges of Preclinical AD Prevention Trials	Jason Karlawish, MD University of Pennsylvania School of Medicine, Philadelphia, PA
	6. Consent for Revealing Biomarker Status in AD Prevention Trials	Scott Roberts, PhD University of Michigan School of Public Health, Ann Arbor, MI
11:15am – 11:30	Break
11:30am – 12:30 pm	Open Discussion Discussant: Philip Scheltens, MD, PhD VU Medical Center, Amsterdam, Netherlands
12:30 – 1:30 pm	LUNCH

Alzheimer's Public Educational Forum

Alzheimer's Disease Prevention Trials

Sunday, JANUARY 20, 2013
2:00 pm – 5:30 pm
Chair: Eric M. Reiman, MD, Banner Alzheimer's Institute, Phoenix, AZ

2:00 – 2:10 pm	Introduction to the Educational Forum	Ranjan Duara, MD Mount Sinai Medical Center, Miami Beach, FL
2:10 – 4:30 pm	Measuring Progression in Alzheimer's Disease Using Brain Imaging Tests	Susan Landau, PhD University of California, Berkeley, CA
	Questions and Answers
	Treating Alzheimer's Before Symptoms Begin	Reisa A. Sperling, MD, MMSc, Massachusetts General Hospital and Harvard Medical School, Boston, MA
	Questions and Answers
	What We Know About the Genetics of Alzheimer's Disease	Allan Levey, MD, PhD Emory University School of Medicine, Atlanta, GA
	Questions and Answers
	The Importance of Being Informed and Participating in Trials	Maria Carillo, PhD Alzheimer's Association, Chicago, IL
	Questions and Answers
4:30 – 5:30 pm	Questions from the Audience and Panel Discussion Panelists: Maria Carillo, John C. Morris, Steve Salloway, Eric Reiman, Reisa A. Sperling, Scott Roberts